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Summary
K-ras mutations are found in 40–50% of human colorectal adenomas and carcinomas, but
their functional contribution remains incompletely understood. Here, we show that a condi-
tional mutant K-ras mouse model (K-rasAsp12 ⁄Cre), with transient intestinal Cre activation
by b-Naphthoflavone (b-NF) treatment, displayed transgene recombination and K-rasAsp12
expression in the murine intestines, but developed few intestinal adenomas over 2 years.
However, when crossed with ApcMin ⁄ + mice, the K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + offspring showed
acceleration of intestinal tumourigenesis with significantly changed average lifespan
(P < 0.05) decreased to 18.4 ± 5.4 weeks from 20.9 ± 4.7 weeks (control ApcMin ⁄ + mice).
The numbers of adenomas in the small intestine and large intestine were significantly
(P < 0.01) increased by 1.5-fold and 5.7-fold, respectively, in K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice
compared with ApcMin ⁄ + mice, with the more marked increase in adenoma prevalence in the
large intestine. To explore possible mechanisms for K-rasAsp12 and ApcMin co-operation, the
Mitogen-activated protein kinase (Mapk), Akt and Wnt signalling pathways, including
selected target gene expression levels, were evaluated in normal large intestine and large
intestinal tumours. K-rasAsp12 increased activation of Mapk and Akt signalling pathway tar-
gets phospho-extracellular signal-regulated kinase (pErk) and pAkt, and increased relative
expression levels of Wnt pathway targets vascular endothelial growth factor (VEGF), gas-
trin, cyclo-oxygenase 2 (Cox2) and T-cell lymphoma invasion and metastasis 1 (Tiam1) in
K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + adenomas compared with that of ApcMin ⁄ + adenomas, although
other Wnt signalling pathway target genes such as Peroxisome proliferator-activated recep-
tor delta (PPARd), matrix metalloproteinase 7 (MMP7), protein phosphatase 1 alpha
(PP1A) and c-myc remained unchanged. In conclusion, intestinal expression of K-rasAsp12
promotes mutant Apc-initiated intestinal adenoma formation in vivo more in the large intes-
tine than the small intestine, with evidence of synergistic co-operation between mutant
K-ras and Apc involving increased expression of some Wnt-pathway target genes.
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Colorectal cancers arise following accumulation of muta-
tions or other alterations to several genes, including Apc
(adenomatous polyposis coli), b-catenin, K-ras, Smad 2 & 4,
PI3k, Msh2, Mlh1, p53 and others, along with large-scale
genomic changes and epigenetic alterations (Fearon & Vo-
gelstein 1990; Powell et al. 1992; Al-Aynati et al. 2004; Ar-
ends & Frayling 2005; Sjo¨blom et al. 2006; Wood et al.
2007). K-ras is mutated in 40–50% of both colorectal ade-
nomas and carcinomas, with codon 12 aspartate as one of
the common mutations (Bos et al. 1987; Jervoise et al.
1998; Andreyev et al. 2001). K-ras mutations may be found
at all stages of colorectal neoplasm development, including
dysplastic aberrant crypt foci (ACF) (Shivapurkar et al.
1997), hyperplastic polyps (Otori et al. 1997), adenomas
and carcinomas (Ohnishi et al. 1997). K-ras mutations are
associated with increased size and dysplasia in adenomas,
suggesting that they may be permissive for growth disorder
early in tumourigenesis (Ohnishi et al. 1997). Mutation of
the K-ras gene reduces or abolishes the protein’s intrinsic
GTPase activity, locking it in a guanosine triphosphate
(GTP) bound conformation that is constitutively active and
generates signals to downstream effectors (Barbacid 1987).
This activation of ras has several effects on rodent fibro-
blasts cultured in vitro, including the establishment of the
transformed phenotype, anchorage independent growth,
focus formation and tumourigenic potential when injected
into animals (Spandidos & Wilkie 1984; Arends et al. 1993,
1994), but its roles in colorectal tumour initiation and pro-
gression are still incompletely understood.
The Apc gene, frequently called the ‘gatekeeper’ of colo-
rectal cancer, is mutated in 60–80% of sporadic colorectal
adenomas and cancers. Inherited Apc defects give rise to the
syndrome of familial adenomatous polyposis coli (FAP)
manifested by the formation of hundreds or thousands of
adenomas (Rustgi 1994). Familial adenomatous polyposis
coli (FAP) is modelled by the multiple intestinal neoplasia
(ApcMin ⁄ +) mouse, which has one wild-type allele and one
Apc allele mutated at codon 850, and displays Apc-driven
tumourigenesis in the intestines (Su et al. 1992). Investiga-
tion of adenomas from both FAP patients and Min mice
(each with one inherited Apc gene mutation) has shown
either mutation or loss of the wild-type Apc allele in most
adenomas (Ichii et al. 1993; Levy et al. 1994). Thus, muta-
tion or loss of both Apc alleles represents the most impor-
tant pathway of adenoma initiation.
K-ras and Apc mutations both occur during the early
stages of colorectal adenoma formation, including dysplastic
aberrant crypt foci, early monocryptal adenomas, oligocryp-
tal adenomas as well as established adenomas, and it has
been hypothesized that these two mutant genes may co-oper-
ate during tumourigenesis. Previously, we showed that
induction of intestinal expression of a similar conditional
knock-in K-rasVal12 transgene can accelerate intestinal
tumour formation on a Msh2-null background (Luo et al.
2007a); however, the precise contributions of mutated K-ras
to mutant Apc-driven intestinal tumourigenesis are insuffi-
ciently well characterized. In vitro studies have shown syn-
ergy between mutant ras and Apc, as together they promote
transformation of colonic epithelial cell lines (D’Abaco et al.
1996), but the results of in vivo experiments have been con-
tradictory (Johnson et al. 2001; Janssen et al. 2002, 2005,
2006; Guerra et al. 2003; Tuveson et al. 2004; Sansom
et al. 2006; Calcagno et al. 2008; Haigis et al. 2008). Onco-
genic K-ras has been shown to co-operate with mutant Apc
during tumourigenesis affecting the intestines (Janssen et al.
2006; Sansom et al. 2006; Haigis et al. 2008), but the mech-
anisms are incompletely understood and the site of maximal
co-operation within the small or large intestines is uncertain.
Here, we describe a strain of mice with a conditional
mutated K-rasAsp12 transgene that when crossed with Ah-
Cre mice, allows inducible expression of K-rasAsp12 in the
intestinal epithelial stem cell compartment of the crypts.
This model was used to test the effect of mutant K-rasAsp12
on intestinal tumourigenesis in vivo. In mice carrying a
mutant K-rasAsp12 transgene and Ah-Cre, following induc-
tion of recombination and expression of mutated K-rasAsp12
in the intestines, only a few small adenomas were found in
the small intestine, showing that mutant K-ras alone does
not significantly initiate tumour formation in the intestine,
confirming our previous findings (Luo et al. 2007a). The
mutant K-rasAsp12 ⁄Ah-Cre transgenic mice were crossed with
ApcMin ⁄ + mice and the progeny harbouring mutated K-
rasAsp12, Ah-Cre and ApcMin ⁄ + alleles showed acceleration of
intestinal tumourigenesis, with greater effects on the large
than the small intestines, and the adenomas showed evidence
of synergism between mutant K-ras and Apc involving
increased expression of some Wnt-pathway target genes.
Materials and methods
Transgene construction
The K-rasAsp12 transgene expression construct was generated
as follows: the oncogenic ras gene was a previously made
chimeric human N ⁄K-ras gene (Maher et al. 1995), which
contained the cDNA sequence encoding amino acids 1–83
from the human N-ras, including a mutation in codon 12
coding for an aspartic acid residue (Asp) instead of the wild-
type glycine, fused with the cDNA sequence encoding amino
acids 84–188 from the human K-ras gene that includes exon
Mutant K-ras accelerates Min tumourigenesis 559
 2009 The Authors
Journal compilation  2009 Blackwell Publishing Ltd, International Journal of Experimental Pathology, 90, 558–574
4B in continuity with exon 3 (excluding exon 4A). The
entire chimaeric ras gene encodes the correct primary amino
acid sequence for the human K-RasAsp12 4B protein, because
K-Ras and N-Ras proteins share the same amino acid
sequence for the first 83 residues. This chimaeric K-rasAsp12
transgene cDNA fragment was inserted into the Promega
vector PCIneo that featured a floxed-‘STOP’ cassette, con-
structed as described elsewhere (Brooks et al. 2001; James
et al. 2003; Luo et al. 2007a) using the synthetic linker NotI
– LoxP – HindIII–XhoI – LoxP – NotI (5¢-GGC CGC ATA
ACT TCG TAT AGC ATA CAT TAT ACG AAG TTA
TAA GCT TAT TTG AGG CTC GAG AAA TAA CTT
CGT ATA GCA TAC AT T ATA CGA AGT TAT AGC
TGG C-3¢) and the neomycin resistance gene containing
‘STOP’ sequence inserted into the HindIII and XhoI sites.
Upstream of this lox-STOP-lox sequence was placed the
cytomegalovirus (CMV) promoter and downstream was the
K-rasAsp12 transgene followed by an encephalomyocarditis
virus internal ribosome entry site (IRES)–enhanced green
fluorescent protein (EGFP) sequence (Figure 1). This con-
struct was linearized by BamHI, purified by agarose gel elec-
trophoresis with electroelution and injected into fertilized
FVB ⁄N mouse oocytes to generate founder mice.
Genotyping the K-rasAsp12 mice
For genotyping, four pairs of primers, located in the
sequences for the CMV promoter, neomycin resistance gene,
human K-ras exon 4B and EGFP sequences, were designed
and developed (Luo et al. 2007a) for PCR assays for rapid
screening of the K-rasAsp12 positive mice (Figure 1). Tail tips
of offspring were digested overnight at 55 C in 500 ll DNA
lysis buffer (50 mmol ⁄ l Tris-HCl, pH 7.5, 0.1 mol ⁄ l NaCl,
0.5% SDS, 5 mmol ⁄ l ethylene diamine tetra-acetic acid
(EDTA), 100 lg ⁄ml proteinase K). Proteins were precipitated
with 6 mol ⁄ l NaCl. To precipitate DNA, one volume of iso-
propanol was added and the mixture centrifuged, the DNA
pellet was washed in 70% ethanol and dissolved in 30 ll TE
buffer. The quality of genomic DNA samples was estimated
by amplifying a wild-type Apc gene fragment (Luo et al.
2007a). Polymerase chain reaction conditions were 95.0 C
for 30 s, 60.0 C for 30 s and 72.0 C for 45 s for 35 cycles.
Genotyping the ApcMin ⁄ + mice
ApcMin ⁄ + mice have a nonsense mutation at codon 850 in the
Apc gene (Su et al. 1992). We designed four pairs of PCR
primers to distinguish this point mutation from the wild-type
sequence. The first two primer pairs were used under very
strict PCR conditions (95.0 C for 30 s, 66.5 C for 30 s and
72.0 C for 45 s for 35 cycles), the primer pair Apc1a–Apc1b
amplified wild-type Apc gene fragments, whereas the primer
Apc2b (which has just one base difference at the 3¢ terminus
of the primer) was used in the primer pair Apc1a–Apc2b to
amplify the mutant Apc sequence. The second two primer
pairs were also used under strict PCR conditions (95.0 C for
30 s, 72.0 C for 75 s for 35 cycles), the primer pair Apc1c–
Apc1d amplified wild-type Apc sequence, whereas the primer
Apc2d (with just one base difference at the 3¢ terminus of the
primer) was used in the primer pair Apc1c–Apc2d to amplify
the mutant Apc gene sequence. The sequences of PCR primers
were as follows: Apc1a, 5¢ GTT CTC GTT CTG AGA AAG
ACA GAA GTT T 3¢; Apc2b, 5¢ GTT CTC GTT CTG AGA
AAG ACA GAA GTT A 3¢; Apc1b, 5¢ TCG TTT ATA TTC
CAC TTT GGC ATA AGG C 3¢; Apc1c, 5¢ CAA GTC TGC
CAT CCC TTC ACG TTA GGA A 3¢; Apc1d, 5¢ CTG AGG
CCA ATA CCT CGC TCT CTC TCC A 3¢; Apc2d, 5¢ CTG
AGG CCA ATA CCT CGC TCT CTC TCC T 3¢. The opti-
mal primer annealing temperatures were determined by test-
ing the primer pairs against known wild-type Apc sequences
(C57Black6 ⁄ J or B6 mice) and known ApcMin sequences
(known Min mice with multiple adenomas and known muta-
tional status proven by DNA sequencing) at a range of
annealing temperatures on a gradient PCR block (Figure 1c).
Real-time quantitative DNA PCR was used to identify
the copy number of the K-rasAsp12 transgene
To estimate the number of copies of human K-rasAsp12
transgene integrated into the genome of the K-rasAsp12
transgenic mice, real-time quantitative DNA PCR (qPCR)
was used to amplify K-ras sequences from both endoge-
nous murine K-ras proto-oncogene (two copies per cell)
and the integrated human K-rasAsp12 transgenes. One pair
of primers was designed that bound with identical specific-
ity to both human and mouse K-ras exon three sequences:
K-ras mouse ⁄human exon 3 sense primer: 5¢ TTA TTG
ATG GAG AAA CCT GTC TCT TG 3¢, K-ras mouse ⁄hu-
man exon 3 antisense primer: 5¢ TTA TGG CAA ATA
CAC AAA GAA AGC C 3¢. Briefly, 100 ng genomic DNA
extracted from control B6 mice and from mice containing
the K-rasAsp12 transgene was used for qPCR. The qPCR
reactions were amplified using the iCycler (BioRad, Hemel
Hempstead, UK) starting with denaturation at 95.0 C for
3 min, then 35 cycles of 95.0 C for 15 s and 60.0 C for
1 min. The specificity of the PCR reactions was deter-
mined from the dissociation curve analysis and 2%
agarose gel electrophoresis of the products. All PCR prod-
ucts were quantitatively analysed in the linear range of
the log-plotted exponential phase of PCR amplification.
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The quantity of the specific K-ras-derived fragments was
obtained from standard curves with normalization using
the wild-type Apc gene PCR of the same sample. All
qPCR reactions were performed in triplicate and the mean
(±SD) value of K-ras copy number was calculated.
Analysis of transgene recombination at the LoxP sites by
PCR and DNA sequencing
Genomic DNA was prepared from intestinal tumours and
non-tumour-bearing tissue samples by overnight proteinase K
digestion, followed by purification using a QIAamp Tissue kit
(Qiagen, UK). Transgene recombination was detected by PCR
using the primers: sense primer RE-CMV, 5¢ TCA GAT CAC
TAG AAG CTT TAT TGC GG 3¢, which was located in the
CMV promoter; antisense primer RE-K-rasAsp12, 5¢ TAC
AAA GTG GTT CTG GAT TAG CTG GA 3¢, which was
located in exon 3 of the K-rasAsp12 transgene. The PCR prim-
ers were used in a PCR assay to detect recombination at the
two LoxP sites leading to excision of the ‘STOP’ cassette and
joining together of the CMV promoter and the K-rasAsp12
transgene. The same PCR primers were used as DNA
sequencing primers to sequence the PCR product from both
ends by standard Sanger DNA sequencing methods.
Reverse transcription PCR analysis of expression of
K-rasAsp12 transcripts
To induce Cre expression via the Ah promoter of the
Ah-Cre transgene, the mice were injected with 160 mg ⁄kg b-
naphthoflavone (b-NF) (Sigma, Dorset, UK) dissolved in
corn oil for 6 days as described previously elsewhere (Ireland
et al. 2004; Luo et al. 2007a), and controls received either
no treatment or corn oil only. Human K-rasAsp12 4B expres-
sion was determined using the K-ras 4B upstream primer 5¢-
GTA CCT ATG GTC CTA GTA GGA AAT AAA-3¢ located
in human K-ras exon 3; and the K-ras 4B downstream pri-
mer 5¢-CTG ATG TTT CAA TAA AGG AAT TCC A-3¢
located in human K-ras exon 4B. The PCR product size was
159 bp. For quantitative RT-PCR, 100 ng of total RNA of
different tissue samples was reverse transcribed in 25 ml vol-
ume using the iTaq SYBR Green kit RT-PCR kit (BioRad).
All RT-qPCR reactions were amplified starting with denatur-
ation at 95.0 C for 3 min, then 45 cycles of 95.0 C for
15 s and 60.0 C for 1 min.
Western blot and immunohistochemical analyses
For Western blot analysis, fresh tissue samples were lysed in
protein lysis buffer containing 50 mmol ⁄ l Tris–HCl (pH 7.4),
150 mmol ⁄ l NaCl, 0.5% NP-40 (Shell Chemical Co., New
York, USA) and protease inhibitors. Soluble protein lysates
were quantified using the BCA Protein Assay kit (Pierce,
Rockford, Illinois, USA). Total proteins were separated by
15% SDS-PAGE, transferred to nitrocellulose membranes
(Schleicher and Scheull, UK) and incubated with the corre-
sponding antibodies including anti-K-RasAsp12 (Calbiochem,
Merck, Darmstadt, Germany) and anti-Cre rabbit polyclonal
antibody (Novagen Inc., Madison, Wisconsin, USA). Blots
were hybridized with antibodies in 1:1000 dilutions.
Visualization was performed with chemiluminescence. The
p-Mapk Family (including phospho-extracellular signal-
regulated kinase (pErk) 1&2) Rabbit mAb Sampler Kit and
the p-Akt Pathway Sampler Kit (Cell Signalling Co., Beverley,
Massachusetts, USA) were used for Mapk and Akt pathway
protein analysis by both Western blotting and immunohisto-
chemical analyses. Immunohistochemical analysis of selected
proteins involved use of goat anti-gastrin polyclonal antibody,
rabbit anti-T-cell lymphoma invasion and metastasis 1
(Tiam1) (C-16) polyclonal antibody (both from Santa Cruz
Biotechnology Inc., Santa Cruz, California, USA), rabbit
anti-cyclo-oxygenase 2 (Cox2) monoclonal antibody, rabbit
anti-b-catenin monoclonal antibody, rabbit anti-phospho-
GSK-3beta (Glycogen synthase kinase 3beta) monoclonal
antibodies and rabbit anti-Vascular endothelial growth factor
(VEGF) polyclonal antibody (all from Novus Biologicals Inc.,
Littleton, Colorado, USA).
For immunohistochemical analysis, immunoperoxidase
detection was performed on 4 lm formalin-fixed, paraffin-
embedded tissue sections. Sections were deparaffinized in
xylene and rehydrated through graded alcohols to distilled
water. Antigen retrieval was performed. The anti-phospho-
Erk1 ⁄2 primary antibodies, anti-phospho-Akt primary
antibodies, anti-phosphoGSK-3beta primary antibodies,
anti-gastrin primary antibodies, anti-Tiam1 primary anti-
bodies, anti-Cox2 primary antibodies, anti-b-catenin primary
antibodies and anti-VEGF primary antibodies were added to
the sections and incubated for 1 h at room temperature,
followed by biotinylated antibody (Dako, Denmark) and
peroxidase-conjugated ExtroAvidin (Sigma-Aldrich, St Louis,
Missouri, USA). Finally, 3, 3¢-diaminobenzidine tetrahydro-
chloride (DAB) was used as chromogen (Kem-En-Tec A ⁄ S,
Denmark). Sections were counterstained with Mayer’s
haematoxylin. No signal was detected in sections when the
primary antibody was omitted as a negative control.
Analysis of tumours
Mice were killed and the number of intestinal tumours
counted. The whole intestinal tract of each mouse was
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removed, rinsed gently in PBS using a syringe and opened
lengthwise. The opened intestine was spread out flat on filter
paper. All tumours were counted under a dissecting micro-
scope at 15· magnification, always by the same investigator.
The smallest tumours identified were about 0.5 mm in diame-
ter. Some tumours were bisected and half taken fresh for
DNA, RNA and protein analyses. The samples were then fixed
in 10% neutral-buffered formalin solution. Tumours of the
small and large intestines and other tissues were processed for
paraffin embedding. Sections were prepared for H&E staining
for confirmation of the diagnosis and immunohistochemistry.
Real-time quantitative RT-PCR evaluation of relative
expression levels of target genes
Real-time quantitative reverse transcription PCR (real-time
RT-qPCR) was carried out to measure the relative expres-
sion levels of a range of selected target genes (Table 1 shows
the PCR primer sequences) using the comparative cycle
threshold (Ct) method as described elsewhere (Luo et al.
2007a). The values for b-actin were used to normalize the
gene expression data. The gene expression levels in intestinal
tumours relative to the control intestinal normal tissues were
calculated using the following formulas: DDCt = DCt
test)DCt control, fold change = 2)DDCt.
Statistical and clustering analysis
The spss (SPSS, Chicago, Illinois, USA) statistical package
was used for all statistical analyses. Student’s t-tests were
used to compare adenoma numbers, and the Kaplan–Meier
survival curve method with log rank test was used to com-
pare mouse survival data following tumour progression and
mouse deaths. Unsupervised hierarchical clustering of cases
was performed using the Euclidean similarity measure and
Ward linkage (Johnson et al. 2006) and this was carried
out using in-house software written in R (R Development
Core Team. R: A language and environment for statistical
computing. R Foundation for statistical computing: Vienna,
Austria) and visualization was carried out using treeview
1.6 software (Eisen et al. 1998).
Results
Generation and genotyping of conditional K-rasAsp12
transgenic mice and analysis of the transgene copy
number
The conditional K-rasAsp12 transgene is based on chimaeric
cDNA sequences for exons 1, 2, 3 and 4B (but not exon
4A and with no introns), allowing expression of a tran-
script that is translated into a protein with the correct
amino acid sequence for the whole of human K-Ras4B
protein with a codon 12 aspartate mutation (Maher et al.
1995). The structure of the construct was confirmed by
restriction enzyme digestion and DNA sequencing (data
not shown), its expression and correct functioning were
tested in vitro in HM1 murine embryonic stem (ES) cells
(data not shown and Brooks et al. 2001). The K-rasAsp12
transgene construct was linearized by BamHI, purified and
microinjected into fertilized FVB ⁄N mouse oocytes. K-
rasAsp12 transgenic founder mice were generated and
shown to contain the K-rasAsp12 transgene (Figure 1) and
these were subsequently backcrossed with B6 mice for
seven to eight generations until the transgene was on a
congenic B6 background. The K-rasAsp12 positive offspring
mice were identified by PCR assays for the presence of
CMV promoter, human K-ras 4B, neomycin-resistance
gene and EGFP gene sequences (Figure 1b). The exon 3
DNA sequences of both human and mouse K-ras genes
are highly homologous, with a DNA sequence difference
of only two base pairs. A pair of PCR primers was
designed to bind equally to both human and murine K-ras
exon 3 DNA sequences, and real-time quantitative DNA
PCR (qPCR) analysis showed that the relative value of K-
ras exon 3 mean (±SD) copy number in B6 control mice
was 2.00 ± 0.37 (n = 6), whereas that in K-rasAsp12 trans-
genic mice was 3.80 ± 0.55 (n = 6), indicating that B6
control mice have two endogenous copies of K-ras and K-
rasAsp12 transgenic mice have 4 copies, including the two
normal endogenous murine K-ras genes and two copies of
the K-rasAsp12 transgene (Figure 1d).
Genotyping of ApcMin ⁄ + mice
ApcMin ⁄ + mice have a nonsense point mutation at codon
850 in the murine Apc gene (Su et al. 1992). We designed
four pairs of PCR primers to identify this point mutation.
Under very strict PCR conditions (with annealing at
66.5 C), the primer pair Apc1a–Apc1b amplified the
wild-type Apc gene sequence, whereas primer Apc2b
(with just one base difference at the 3¢ terminus of pri-
mer) in the primer pair Apc1a–Apc2b amplified the
mutant Apc gene sequence. Under another set of strict
PCR conditions (with annealing at 72.0 C), the primer
pair Apc1c–Apc1d amplified the wild-type Apc gene
sequence, whereas primer Apc2d (with just one base dif-
ference at the 3¢ terminus of primer) in the primer pair
Apc1c–Apc2d amplified the mutant Apc gene sequence
(Figure 1c).
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Conditional recombination and expression of the
K-rasAsp12 transgene in the intestines of K-rasAsp12 ⁄Cre
transgenic mice
K-rasAsp12 transgene positive mice were crossed with Ah-Cre
mice that are capable of transient expression of Cre recom-
binase protein in the epithelial cells of the intestinal crypts,
including the epithelial stem cells, following b-Naphthoflav-
one (b-NF) intraperitoneal injection (Ireland et al. 2004;
Luo et al. 2007a). This generated offspring mice positive for
both conditional K-rasAsp12 and Ah-Cre transgenes, con-
firmed by PCR-based genotyping assays (Figure 1b). A test
group of 25 mice positive for K-rasAsp12 ⁄Cre transgenes
were treated with b-NF (160 mg ⁄Kg per day for 6 days) to
induce transient expression of Cre recombinase protein in
intestinal epithelium.
A PCR assay was used to detect recombination occurring
at the two LoxP sites (flanking the ‘STOP’ cassette), which
amplified the DNA fragment between the two primers (one
situated in the CMV promoter and the other in K-ras exon
3), to produce an approximately 500 bp fragment (indicat-
ing LoxP recombination) amplified from genomic DNA
extracted from both small and large intestines and also from
stomach, liver and spleen, but not from heart, pancreas or
skin (Figure 2). This showed that Cre-mediated recombina-
tion at the two LoxP sites had occurred to excise the large
approximately 2 Kb ‘STOP’ cassette containing the neomy-
cin-resistance gene, bringing together the CMV promoter
sequence and the K-rasAsp12 sequence. This was confirmed
by DNA sequencing of this PCR product which showed that
the neomycin-resistance gene containing ‘STOP’ cassette had
been deleted between the two LoxP sites (with NotI restric-
tion enzyme sites outside of both LoxP sites), leaving only
one LoxP site (flanked by 2 NotI sites) between the CMV
promoter and adjacent K-ras sequence (Figure 2). The
sequencing data also confirmed the presence of DNA
Figure 1 K-rasAsp12 construct, PCR genotyping and construct copy number assay. (a) Structure of the K-rasAsp12 transgene: cytomega-
lovirus (CMV) immediate early promoter; neomycin (NEO), resistance gene; 1, 2, 3 and 4B, K-ras exons 1, 2, 3 and 4B; encephalo-
myocarditis virus internal ribosome entry site (IRES); enhanced green fluorescent protein (EGFP); pA, polyadenylation signal; c,
34 bp LoxP sites; the positions and orientations of the PCR primers used for genotyping analyses are depicted by arrows ( ﬁ ). (b)
Typical results of genotyping PCR assays from offspring of transgenic mice and control (B6) mice. Polymerase chain reaction (PCR)
amplification of an Apc gene fragment was used as the control for the quality of genomic DNA samples. + represents mouse tail
DNA from mice positive for the K-rasAsp12 transgene; ) represents mouse tail DNA from control B6 mice negative for the transgene
constructs. (c) Genotyping Min mice by allele-specific primers binding either the wild-type or the mutant Apc gene sequence. Upper
two panels: use of Apc1a ⁄Apc1b (wild-type Apc primer pair) and Apc1a ⁄Apc2b (mutant Apc primer pair) to amplify wild-type B6
genomic DNA, shows that at 66 C and 67 C annealing temperatures, wild-type Apc can be distinguished from mutant Apc. Middle
two panels: use of Apc1c ⁄Apc1d (wild-type Apc primer pair) and Apc1c ⁄Apc2d (mutant Apc primer pair) to amplify wild-type B6
genomic DNA, shows that at 72 C annealing temperature wild-type Apc can be distinguished from mutant Apc. Lower two panels:
an example of the use of both sets of wild-type and mutant Apc primer pairs Apc1a ⁄Apc1b (W) and Apc1a ⁄Apc2b (M) at 66.5 C
(upper) and Apc1c ⁄Apc1d (W) and Apc1c ⁄Apc2d (M) at 72 C (lower) to amplify genomic tail DNA samples from known negative
control B6 (wild-type only) and known Min (M1 to M3, with both wild-type and mutant Apc alleles) mice. (d) Bar chart of relative
copy numbers of K-ras exon 3 sequences (human and mouse) by Real-time quantitative DNA PCR (qPCR), showing the mean (error
bar = SD) relative copy number of K-ras exon 3 in B6 control mice was 2.00 ± 0.37 (n = 6), and that of K-rasAsp12 was 3.80 ± 0.55
(n = 6), indicating the presence of two endogenous and two transgenic copies of K-ras.
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sequence encoding aspartate (in K-rasAsp12 ⁄Cre transgenic
mice) at codon 12 (substituted for the wild-type glycine)
(Figure 2c).
Reverse transcription polymerase chain reaction (RT-
PCR) analysis confirmed the expression of human K-ras
4B transcripts in the small and the large intestine and also
in some other tissues (stomach, spleen and liver), but not
in heart, in K-rasAsp12 ⁄Cre mice (but not in K-rasAsp12
transgenic mice that were negative for Cre or in Cre only
mice or control B6 mice) after b-NF treatment
(Figure 3a).
Phenotypic changes in K-rasAsp12 ⁄Cre mice
After treatment with b-NF, the only phenotypic changes
detected in the intestines were two adenomas in the small
intestine and two adenomas in the large intestine in the
group of 25 K-rasAsp12 ⁄Cre mice over 2 years, along with
one sarcoma and two lymphomas, but these differences were
not statistically significant from the control group of B6
mice (n = 16) or Cre-only mice (n = 29) (treated in the same
way) over the same 2-year period. Thus, intestinal expres-
sion of mutant K-rasAsp12 alone is not sufficient to signifi-
cantly initiate intestinal adenomagenesis.
Phenotypic changes in K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice
ApcMin ⁄ + mice on a B6 background typically develop 30–50
intestinal adenomas ⁄mouse in the first 6 months of life. To
assess the effect of mutated K-ras on intestinal tumourigene-
sis initiated by mutant Apc, we crossed K-rasAsp12 ⁄Cre mice
with ApcMin ⁄ + mice to generate a cohort of compound K-
rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice (n = 25). Four weeks after birth,
160 mg ⁄kg b-NF was injected intraperitoneally for 6 days.
A control cohort of ApcMin ⁄ + mice and ApcMin ⁄ + ⁄Cre mice
(n = 29) were also treated in the same way. Some of the
Table 1 Polymerase chain reaction primers for expression analysis
Gene Upstream PCR primer Downstream PCR primer
Axin TCTCCGAGACAGAGACAAAATCAC TCTTGGTTAGCAGCTCCTTGAACT
Apc TGATACTTCTTCCAAAGCTTTGGCTAT TCTCGTTCTGAGAAAGACAGAAGCT
b-catenin CCATTGAAAATATCCAAAGAGTAGC CTCAGACATTCGGAATAGGACAG
CD44 GCGGTCAATAGTAGGAGAAGGTGT CTCGTCAGCTGTCATACACTGGT
CMV TGACGTCAATGGGTGGAGTA TGCCAAAACAAACTCCCATT
c-myc AAATCCTGTACCTCGTCCGATTC ATCAATTTCTTCCTCATCTTCTTGC
Cox2 ACAGACTGTGCCACATACTCAAGC GATACTGGAACTGCTGGTTGAAAAG
Cyclin D1 TTTCTTTCCAGAGTCATCAAGTGTG ACCAGCCTCTTCCTCCACTTC
Cyclin D2 GAACTGGTAGTGTTGGGTAAGCTG GTACATGGCAAACTTGAAGTCG
E-cadherin TACCCGGGACAATGTGTATTACTAT GAAGTTTCCAATTTCATCAGGATT
EGFP GCAAGGGCGAGGAGCTGTTC CCATGCCGAGAGTGATCCCG
Ephb2 CCATTGAACAGGACTACAGACTACC CACCGTGTTAAAGCTGGTGTAG
Gastrin ACCAATGAGGACCTGGAACAG TGCTAGTCCTACTGGTCTTCCTCA
Igfbp4 CACGAAGACCTCTTCATCATCC CCTAGTAGGGGGCACTGAGTC
K-ras 4B TCTTAAGGCATACTAGTACAAGTGGT TTTGTTTCACACCAACATTCA
MMP7 GAGTACTGGACTGATGGTGAGGAC CATATAACTTCTGAATGCCTGCAA
Neo TGGAGAGGCTATTCGGCTATGACTGGG TGGATACTTTCTCGGCAGGAGCAAGGTG
N ⁄K-ras AGTGGTTATAGATGGTGAAACCTGTT TTGTCTTTGCTGATGTTTCAATAAAA
PP1A CTACTGTGTGATCTCCTGTGGTCT AGAAGAGTGTCACCAACTGTCTCTT
P21 CTGTCTTGCACTCTGGTGTCTG GGCACTTCAGGGTTTTCTCTT
PP2A GAATGACTACACTCTTCTGCATCAA TATCAAGAATGGGTCCTATCTTCTG
P70S6K ATCTGAAGAGGATGTGAGTCAGTTT TGTTCGTGGACTACCAATAAATCTT
Pem GAGTCAAGGAAGACTCGGAAGA GGCCTTTTCCTCCATTTAATTC
PPARd CAAGTTCGAGTTTGCTGTCAAGTT GACCTGCAGATGGAATTCTAGAGC
TCF-4 ACCATGTTGATCACAGACACCAA GCTGCAGGTGCTGGATGTT
Tcl-1 CAAGAGTAATGAAAAATTCCAGGTG GATATGGTACAGGATCTGCCAATAC
Tiam1 AATTGTCCACGTGAAATCAGAGT CTTTAAGCGCACACAATCTCTTG
Trap1a AAGAATTGGAGAACCTGATGGA GGGTCGTGGAAGAAATAAATCA
UPA ATCTTGCACGAATACTACAGGGAAG CAGTGATCTCACAGTCTGAACCAAA
VEGF GGAGTACCCCGACGAGATAGAGTA GAAGCTCATCTCTCCTATGTGCTG
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ApcMin ⁄ + mice developed a few colonic adenomatous
tumours, but most of the adenomas of the gastrointestinal
tract were found in the small intestine as expected. The
compound mutant transgenic offspring showed significantly
reduced survival (P < 0.05 by log rank test) due to multiple
intestinal adenoma formation (Figure 4), with bowel
obstruction and ⁄or haemorrhage. The average lifespan was
decreased from 20.9 ± 4.7 weeks (mean ± SD in ApcMin ⁄ +
mice) to 18.4 ± 5.4 weeks (in K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice,
P < 0.05), and no sex differences were observed (Figure 4).
The number of duodenal tumours increased from 4.5 ± 1.99
(in ApcMin ⁄ + mice) to 7.2 ± 3.04 (in K-rasAsp12 ⁄Cre ⁄
ApcMin ⁄ + mice, P < 0.01); the number of jejunal tumours
increased from 17.9 ± 6.96 (in ApcMin ⁄ + mice) to
27.2 ± 8.05 (in K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice, P < 0.01);
the number of ileal tumours increased from 9.7 ± 3.51 (in
ApcMin ⁄ + mice) to 15.3 ± 3.45 (in K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ +
mice, P < 0.01). Thus, there was a 1.5-fold increase in total
numbers of small intestinal adenomas in the K-rasAsp12 ⁄ -
Cre ⁄ApcMin ⁄ + mice. The number of proximal colonic adeno-
mas increased from 0.22 ± 0.48 (in ApcMin ⁄ + mice) to
1.56 ± 0.99 (in K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice, P < 0.01);
the number of distal colonic adenomatous tumours increased
from 0.41 ± 0.68 (in ApcMin ⁄ + mice) to 2.04 ± 1.66 (in K-
rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice, P < 0.01). Thus, compared
with ApcMin ⁄ + mice, there was a 5.7-fold increase in total
numbers of large intestinal adenomas in the K-rasAsp12 ⁄ -
Cre ⁄ApcMin ⁄ + mice (Figure 4). Histological examination con-
firmed the presence of closely similar adenomas with low
grade dysplasia in both the test and control cohorts, and no
invasive carcinomas were identified. In the control ApcMin ⁄ +
group, 22 large intestinal tumours were measured for
Figure 2 Analysis of conditional K-rasAsp12 transgene recombination. (a) Schematic representations of the K-rasAsp12 construct
undergoing recombination (after treatment with b-NF to induce Cre expression) at the two LoxP sites to bring about expression of
K-rasAsp12 transcripts. Without Cre recombinase expression, the K-rasAsp12 transgenes remain silent due to the presence of the neomy-
cin (NEO) containing ‘STOP’ cassette. Upon Cre-mediated recombination of the LoxP sites (arrowheads), the K-rasAsp12 transgene is
placed directly under the control of the cytomegalovirus (CMV) promoter. Position and orientation of the polymerase chain reaction
(PCR) primers used for analysis are depicted by arrows ( ﬁ ). (b) PCR amplification of the DNA fragment between the CMV pro-
moter and K-rasAsp12 exon 3 generated a 500-bp fragment from genomic DNA extracted from the intestines and some other tissues.
B6, Black6 wild-type; C, Cre-only genotype; K ⁄C, K-rasAsp12 ⁄Cre genotypes; SI, small intestine; LI, large intestine; Sp, spleen; St,
stomach; Pan; pancreas; Sk, skin; Liv, liver; H, heart. (c) DNA sequencing traces of the 500-bp amplified products showed that the
‘STOP’ cassette had been deleted and there was only one LoxP site (flanked by two NotI restriction enzyme sites) between the
sequences of the CMV promoter and K-ras exon 1, with the appropriate codon 12 mutation for the transgene construct: codon 12
GAT in the K-rasAsp12 mouse intestine.
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tumour size: 14 tumours measured 1–2 mm in diameter and
eight tumours measured 2–4 mm in diameter (36.4%
tumours measured ‡ 2 mm). For the test cohort of K-
rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice, 49 large intestinal tumours
measured 1–2 mm in diameter and 36 measured 2–4 mm in
diameter (42.4% tumours measured ‡ 2 mm, with no signif-
icant difference between the two groups). However, two
tumours in the K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + group were more
than 4 mm in diameter.
Analysis of intestinal adenomas for transgene
recombination and expression of K-rasAsp12
To determine the proportion of intestinal adenomatous
tumours in which K-rasAsp12 transgene recombination and
expression occurred following b-NF treatment of the K-
rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice, a sample of large intestinal
tumours (LITs) and small intestinal tumours (SITs) were
tested for evidence of transgene recombination by PCR
(using the same assay as described above) and K-rasAsp12
transcript and protein expression (by RT-PCR analysis as
described earlier and by Western blot analysis). Genomic
DNA analysis showed that K-rasAsp12 transgene recombina-
tion occurred in 23 of 25 (92%) LITs from K-rasAsp12 ⁄
Cre ⁄ApcMin ⁄ + mice (Figure 3b). Those tumours taken from
the K-rasAsp12 ⁄Cre ApcMin ⁄ + mice with transgene recombina-
tion demonstrated expression of K-rasAsp12 4B transcripts by
RT-PCR analysis. Western blot analysis using specific anti-
K-RasAsp12 protein antibody confirmed expression of mutant
K-Ras protein in these LIT from b-NF treated K-rasAsp12 ⁄
Cre ⁄ApcMin ⁄ + mice (Figure 3d).
Figure 3 Expression of K-rasAsp12 in intestinal tissues and
tumours. (a) Reverse transcription polymerase chain reaction
(RT-PCR) analysis of the expression of K-rasAsp12 4B transcripts
in different tissues of K-rasAsp12 ⁄Cre transgenic mice, 10 days
after completion of the b-NF treatment. C, Cre-only genotype,
K ⁄C, K-rasAsp12/Cre genotypes; LI, large intestine; SI, small
intestine; St, stomach; Sp, spleen; Sk, skin and Liv, liver as
described previously. (b) PCR amplification of a 500-bp DNA
fragment between the recombined CMV promoter and
K-rasAsp12 exon 3 from genomic DNA of large intestinal
tumours (LIT) from K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + transgenic mice
treated with b-NF (Apc amplification as control). (c) RT-PCR
analysis of the expression of K-rasAsp12 4B transcripts in two
small intestinal tumours (SIT) and two LIT from K-rasAsp12 ⁄
Cre ⁄ApcMin ⁄ + (K ⁄C ⁄M) mice after treatment with b-NF (b-actin
RNA expression as normalization reference). (d) Western blot
analysis of the expression of mutant K-RasAsp12 protein in a
large intestinal tumour of a K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + (K ⁄C ⁄M-
LIT) mouse after b-NF treatment (b-actin protein expression as
control) compared with a Cre-only mouse large intestine (C-LI).
Figure 4 Intestinal tumour prevalence and lifespan in ApcMin ⁄ +
mice and K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice. (A & B) Average num-
bers of small intestinal tumours (a) and large intestinal tumours
(b) in K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice (speckled bars), compared
with control ApcMin ⁄ + and ApcMin ⁄ + ⁄Cre mice (open bars).
(c) Kaplan–Meier survival curves of Cre mice (n = 29), ApcMin ⁄ +
(n = 29 in total, including 21 ApcMin ⁄ + and 8 ApcMin ⁄ + ⁄Cre
mice), and K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice (n = 25). Ages of the
animals at death (or when killed, if moribund) are given in
weeks (X-axis).
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Effects on target gene expression of the K-ras ⁄Mapk ⁄Akt
and Wnt signalling pathways
Previous studies have shown that when mutant K-rasVal12
transgene was introduced into either mouse embryonic stem
cells or K-rasVal12 ⁄Cre ⁄Msh2) ⁄ ) transgenic mice, the expres-
sion of human K-rasVal12 was associated with changes in the
expression of a range of gene transcripts and proteins,
including stem cell-associated genes, such as Pem, Tcl-1 and
Trap, and with increased phosphorylation of Mapk and Akt
pathway proteins, such as pErk1&2 and pAkt (Luo et al.
2007a,b). Here, we used both immunohistochemistry, to
show differences in target gene product expression in adeno-
mas (Figure 5), and real-time quantitative reverse transcrip-
tion PCR assays (Tables 1 and 2), to compare the relative
RNA expression levels of a selected panel of genes between
non-tumour-bearing normal large intestine (LI) and LITs of
b-NF treated Cre mice, K-rasAsp12 ⁄Cre mice, K-rasAsp12 ⁄ -
Cre ⁄ApcMin ⁄ + mice and ApcMin ⁄ + control mice. Compared
with the Ah-Cre control mice LI, target genes of the Mapk
signalling pathway, such as VEGF, Cox2, Trap, p70S6K
and cyclinD2, showed significant increases in relative expres-
sion levels by real-time qRT-PCR in the normal colonic
tissues of K-rasAsp12 ⁄Cre mice. Normal LI from ApcMin ⁄ +
mice showed a significant increase in relative expression lev-
els of Cox2, uPA, Trap and b-Catenin compared with that
in the normal LI tissues of Cre mice. In large intestinal
tumours from ApcMin ⁄ + mice, there were significant increases
in the relative expression levels of CD44, p70S6K and gas-
trin. Compared with ApcMin ⁄ + mice LITs, the LITs from K-
rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice showed significant increases in
CD44 (1.6-fold), cyclinD2 (4.8-fold), gastrin (5.7-fold),
Figure 5 Immunohistochemical analysis of intestinal adenomas. Large intestinal tumours from ApcMin ⁄ + mice (Min-LIT) and from
K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + transgenic mice (K-ras-Min-LIT) were analysed immunohistochemically for expression of pAkt, pErk 1, 2,
pGSK, gastrin, VEGF, b-catenin, Tiam1 and Cox2.
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VEGF (2.8-fold), Pem (10-fold), Tcl-1 (6.8-fold) and Trap
(19-fold). Immunohistochemistry confirmed mild increases in
protein expression of gastrin and VEGF genes in the LITs
from K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice compared with those of
ApcMin ⁄ + mice, and suggested small increases in expression
of Cox2, b-Catenin and Tiam1. Immunohistochemical stain-
ing confirmed increased expression of the phosphorylated
forms of the downstream phosphoprotein effectors of the
Mapk and Akt signalling pathways, including pErk1&2 and
pAkt, in the LITs of K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice com-
pared with those of ApcMin ⁄ + mice, but little of evidence of
changed expression of pGSK-3beta (Figure 5). Hence, there
was evidence of activation of both Mapk and Akt signalling
pathways in the LITs of K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice as
well as up-regulation of certain other gene targets of the
Wnt ⁄Apc pathway.
Hierarchical cluster analysis of the relative expression
level data determined by real-time qRT-PCR for the
selected target genes showed that the 24 genes were differ-
entially expressed in the normal LI tissues from Cre mice,
K-rasAsp12 ⁄Cre mice, ApcMin ⁄ + mice and K-rasAsp12 ⁄Cre ⁄
ApcMin ⁄ + mice and in the large intestinal tumours (LITs)
of ApcMin ⁄ + mice and of K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice,
and that there was clear evidence of clustering broadly
together of expression patterns in LI tissues and LITs
from mice of the same genotypes (Figure 6). Taken
together with the relative expression levels, these cluster
patterns indicate that expression of mutated K-ras within
mutant Apc-initiated large intestinal tumours consistently
and selectively modulated the expression levels of certain
target genes in both the K-ras ⁄MapK ⁄Akt and the
Wnt ⁄Apc pathways.
Table 2 Relative expression levels for selected genes by real-time quantitative reverse transcription polymerase chain reaction
Gene
C
LI
Ave
(3)
C
LI
SD
K ⁄C
LI
Ave (3)
K ⁄C
LI
SD
K ⁄C vs. C
LI
t-test
M
LI
Ave (3)
M
LI
SD
M vs. C
LI
t-test
M
LIT
Ave (4)
M
LIT
SD
M-LIT
vs. M-LI
t-test
K ⁄C ⁄M
LIT
Ave (5)
K ⁄C ⁄M
LIT
SD
K ⁄C ⁄M-LIT
vs. M-LIT
t-test
CD44 1.52 0.66 3.53 1.11 0.091 1.21 0.22 0.182 2.54 0.52 0.005 4.05 1.52 0.050
cyclin D2 1.06 0.59 2.65 0.18 0.024 2.75 1.50 0.124 3.39 2.65 0.364 16.42 4.51 0.001
PP1A 1.12 0.27 1.90 1.18 0.156 2.34 2.15 0.230 2.90 1.91 0.366 3.51 2.37 0.344
PP2A 0.88 0.10 2.70 1.45 0.085 1.38 0.94 0.206 3.21 1.38 0.053 3.57 1.37 0.354
Axin-2 1.80 0.71 1.98 0.85 0.406 2.16 0.99 0.372 2.52 0.46 0.274 4.35 2.08 0.066
p70S6K 0.95 0.34 3.37 1.24 0.039 0.69 0.13 0.117 4.34 2.69 0.035 6.32 3.45 0.189
E-cadherin 1.56 0.66 2.34 1.045 0.174 2.78 1.45 0.060 3.16 2.68 0.418 6.79 3.67 0.072
p21 1.51 0.46 1.41 1.66 0.453 3.07 1.25 0.055 3.04 2.84 0.495 3.76 3.38 0.373
Igfbp4 1.39 0.96 2.19 1.62 0.294 3.08 2.49 0.117 2.56 1.27 0.365 10.70 12.57 0.122
Cox2 0.89 0.11 2.73 0.54 0.011 3.73 1.23 0.033 5.65 3.83 0.226 13.46 10.67 0.105
TCF-4 1.03 0.31 1.48 0.65 0.241 1.74 1.03 0.117 1.64 1.03 0.450 1.77 0.96 0.422
uPA 1.42 0.52 2.79 0.55 0.075 1.90 0.77 0.043 4.47 4.12 0.173 7.91 2.45 0.081
gastrin 0.93 0.50 0.73 0.29 0.301 0.96 0.19 0.471 1.58 0.40 0.030 8.41 6.81 0.044
VEGF 0.98 0.05 2.02 0.43 0.032 1.50 0.47 0.091 1.68 0.26 0.269 4.65 1.42 0.002
Tiam1 1.18 0.92 1.16 0.15 0.484 1.34 1.12 0.256 3.74 3.40 0.151 3.74 3.87 0.500
cyclin D1 0.85 0.17 0.88 0.24 0.432 1.98 0.87 0.099 3.76 2.00 0.108 2.02 1.09 0.069
MMP7 0.60 0.41 1.86 0.97 0.090 0.67 0.46 0.074 1.24 0.77 0.157 1.28 0.72 0.468
c-Myc 1.10 0.70 1.72 0.47 0.123 1.76 1.27 0.127 3.35 2.97 0.217 3.37 2.24 0.495
PPARd 1.46 0.97 1.21 0.24 0.375 1.72 1.36 0.211 1.13 0.56 0.227 1.73 1.13 0.183
Eph 1.12 0.57 0.79 0.17 0.231 2.06 1.63 0.152 3.79 3.16 0.216 2.35 1.42 0.194
Pem 1.31 1.08 2.11 2.12 0.335 2.12 1.51 0.171 1.87 1.44 0.417 18.95 12.66 0.017
Tcl 1 1.77 1.81 3.39 3.71 0.311 1.28 1.26 0.131 2.33 1.25 0.162 15.87 10.17 0.017
Trap 0.69 0.27 5.85 3.05 0.050 1.90 0.31 0.007 0.93 0.84 0.060 17.81 6.45 0.001
b-catenin 0.93 0.08 1.12 0.29 0.228 2.65 0.85 0.031 2.67 0.43 0.479 2.51 0.58 0.328
Note abbreviations: C, Cre genotype; K ⁄C, K-rasAsp12 ⁄Cre genotype; M, ApcMin ⁄ + genotype; K ⁄C ⁄M, K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + genotype; LI,
large intestine; LIT, large intestinal tumour; Ave, average value; (n), number of samples analysed given in brackets; t-test, Student’s t-test; P
value; statistically significant Student’s t-test P values highlighted in bold.
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Discussion
Human colorectal neoplasia involves transitions from nor-
mal to adenoma to carcinoma associated with accumula-
tion of genetic and epigenetic changes in a multistep
process, including activation of K-ras by somatic mutation
within one or a small number of stem cells located in the
intestinal crypt (Fearon et al. 1987; Wood et al. 2007). K-
ras mutations have been found in aberrant crypt foci
(ACF), early and established adenomas, as well as in can-
cer-predisposed morphologically normal colon (Morris
et al. 1996; Malumbres & Barbacid 2003). Aberrant crypt
foci (ACF) have been shown to contain K-ras mutations,
with little or no evidence for mutations in either Apc or its
downstream effector b-catenin (Takayama et al. 2001).
Several attempts have been made to develop murine models
of mutated K-ras to investigate the role of K-ras mutation
in the development of intestinal neoplasia, with variable
and contradictory results. Transgenic expression of mutant
K-rasVal12 in the small intestine in post-mitotic villus
enterocytes under the control of the rat liver fatty acid
binding protein gene 1 (Fabp1) promoter caused intestinal
dysplasia, but the authors did not observe any tumours,
with mutant K-ras expressed in cells of the villus which are
exfoliated every 2–3 days, thereby quickly eliminating these
mutant cells before tumourigenesis can occur (Kim et al.
1993). Johnson et al. (2001) used a transgenic model, in
which the recombinational activation of the mutant K-ras
was generated at random by recombination occurring within
the manipulated allele and these mice were predisposed to a
Figure 6 Hierarchical cluster analysis of the differential expression patterns of 24 genes in normal colon and large intestinal tumours.
Normal large intestine (LI) tissues from Cre (C), K-rasAsp12 ⁄Cre (K-C) and ApcMin ⁄ + (M) mice and large intestinal tumours (LIT)
from ApcMin ⁄ + (M) and K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + (K-C-M) mice were analysed for the relative expression levels of 24 selected genes
by real-time quantitative reverse transcription polymerase chain reaction (see Table 2): red represents marked overexpression; dark
red ⁄ black represents mild over-expression and green represents unchanged or mildly decreased expression levels, with the fold-change
shown according to the colour key of the row-Z score. T numbers refer to individual samples. There is a pattern of clustering broadly
together of LI tissues and LITs from mice of the same genotypes indicating mostly consistent gene expression changes.
Mutant K-ras accelerates Min tumourigenesis 569
 2009 The Authors
Journal compilation  2009 Blackwell Publishing Ltd, International Journal of Experimental Pathology, 90, 558–574
range of tumour types, predominantly early onset lung can-
cer, but the transgenic mice failed to develop intestinal
tumours. According to the authors, this may have been
due either to tissue-specific differences in the frequency
of recombination events, or to the relative order of ras
gene mutations in the course of intestinal tumourigenesis
(Johnson et al. 2001). Janssen et al. (2002) constructed
mice with a mutated K-ras gene associated with the regula-
tory region of the murine villin promoter, and these villin-
K-rasVal12 mice developed just two tumours over 6 months
(Janssen et al. 2002), but the villin promoter is active dur-
ing murine embryonic development (Robine et al., 1985;
Ezzell et al. 1989). Crossing these villin-K-rasVal12 mice
(with constitutive expression of human K-rasVal12 4B iso-
form) with Apc1638N mice on a crossbred background
resulted in intestinal adenoma formation with some carci-
nomas and there was evidence of Erk activation, but not
Akt activation in intestinal epithelium (Janssen et al. 2006).
Sansom et al. (2006) showed that mice with inducible
expression (via Ah-Cre) of endogenous K-rasVal12 4A and
4B isoforms, when crossed with Apcfl580 mice on a cross-
bred background, developed intestinal adenomas with some
carcinomas, with some focal Erk activation. Whereas Hai-
gis et al. (2008) showed that mice with constitutive expres-
sion (via Fabpl-Cre) of endogenous K-rasAsp12 4A and 4B
isoforms, when crossed with Apc2lox14 mice on a crossbred
background, also formed intestinal adenomas with some
carcinomas, but with no evidence of Erk activation. How-
ever, Calcagno et al. (2008) suggested that K-rasAsp12 may
initiate intestinal neoplasia more in the proximal colon,
with some evidence of increased Erk signalling.
To address the questions whether activated K-rasAsp12 is
able to initiate intestinal tumour formation or rather
depends on previous mutations of the ‘gatekeeper’ gene
Apc, and whether such oncogenic activity is greater in the
small or large intestines, we used a Cre ⁄LoxP-based trans-
genic system with expression of the Cre recombinase under
control of the Ah promoter, which allows activation of Cre
expression in the adult intestinal crypt stem cells with pre-
cise spatial–temporal control (Ireland et al. 2004). Using K-
rasAsp12 ⁄Cre mice treated with bNF to trigger Cre-mediated
recombination and expression of mutated K-rasAsp12 in
small and large intestinal epithelium, we found that only
two of 25 mice developed adenomas in the intestines over
2 years and, therefore, the K-rasAsp12 mutation alone did
not significantly initiate adenoma formation in the intes-
tines. A very small (and non-significant) number of sarco-
mas and lymphomas also developed in other tissues. There
may have been a very low frequency of sporadic ‘leaky’
activation of the Ah-Cre transgene leading to Cre recom-
binase expression and LoxP site recombination to trigger
mutant K-ras expression as a rare event in connective tissue
or lymphoid stem cells. However, the small and large intes-
tines were demonstrated to express mutated K-rasAsp12, but
appeared unable to initiate intestinal tumour formation as
this may require other (possibly multiple) spontaneous
mutations in addition. This is consistent with the hypothe-
sis that a contribution from activated K-ras to intestinal
tumour progression may not occur without the requirement
of mutations to other tumour suppressor genes, such as
Apc (Janssen et al. 2006; Sansom et al. 2006; Haigis et al.
2008).
It is generally accepted that adenomas develop in the
intestines of patients with FAP or in Min mice when an
appropriate cell acquires a somatic mutation or deletion of
the wild-type Apc allele to accompany the pre-existing
germ-line Apc mutation. A polyclonal model of adenoma
formation has also been suggested. Although the initiating
role of Apc mutation is part of most models of colorectal
tumourigenesis, it is not clear whether bi-allelic Apc muta-
tions are sufficient for the growth of early lesions to form
established colorectal adenomas or whether there is a
requirement for mutations at other loci, such as K-ras (Chen
et al. 2004). Sansom et al. (2006) and Haigis et al. (2008)
have shown synergistic co-operation between mutant K-ras
and mutant Apc in kidney tumour formation as well as in
intestinal tumourigenesis.
Here, we have shown that when Ah-Cre-mediated activa-
tion of expression of mutated K-ras is targeted to the adult
intestinal crypt epithelial stem cells, K-rasAsp12 does acceler-
ate intestinal adenoma formation on a background of inher-
ited Apc mutation and the offspring bearing K-
rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mutations showed decreased survival
with significant reductions in the average lifespan and signif-
icant increases in the numbers of both small (1.5-fold) and
large (5.7-fold) intestinal adenomas, with the higher increase
seen in the number of large intestinal tumours, more closely
mimicking the human situation. Thus, this evidence shows
that mutated K-rasAsp12 drives progression, but not initia-
tion, of intestinal adenoma formation with greater effects on
the large intestine.
Expression analysis of the large intestinal tumours from
the K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice, by both immunohisto-
chemistry and real-time quantitative RT-PCR, showed that
mutant K-rasAsp12 modulates the expression of some target
genes of the Mapk, Akt and Wnt pathways. There is immu-
nohistochemical evidence of increased expression of the
phosphorylated forms of the downstream effectors of the
Mapk and Akt signalling pathways, including pErk1&2 and
pAkt, in the LITs of K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice
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compared with those of ApcMin ⁄ + mice, confirming
activation of both Mapk and Akt signalling pathways in
these tumours. Immunohistochemistry also suggested a mild
increase in expression of b-catenin protein, with no signifi-
cant changes in transcript levels, indicating post-translational
regulation of protein levels. Mutant K-ras has previously
been shown to induce the activity of a T cell factor 4 (Tcf-4)
reporter construct in Caco-2 and HeLa cells, leading to sta-
bilization of the levels of nuclear b-catenin and the forma-
tion of nuclear b-catenin ⁄Tcf-4 complexes. Mutant K-ras
has been shown to stimulate Wnt signalling in colonic
cancer through inhibition of GSK-3beta (Li et al. 2005).
Mapk ⁄Erk pathway co-operation with Wnt signalling path-
way could occur at multiple levels, including via Wnt3a and
b-catenin ⁄Tcf-4-dependent gene transcriptional events.
Wnt3a stimulated G1 ⁄ S phase cell cycle progression and this
stimulation was reduced by an Erk pathway inhibitor, indi-
cating that Wnt3a promotes proliferation by stimulating the
Erk pathway (Yun et al. 2005; Kim et al. 2007).
In intestinal tumours from the K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ +
mice, mutated K-ras further enhanced expression of VEGF
compared with that seen in ApcMin ⁄ + mouse adenomas. Vas-
cular endothelial growth factor (VEGF) is a key regulator of
tumour angiogenesis, and angiogenesis is not only restricted
to advanced stages of tumour development, but is also
observed in benign intestinal adenomas, and VEGF can also
modulate cellular proliferation, transformation and tumour
growth. Mutant K-ras up-regulated the expression of VEGF
in this model and this has been shown previously to occur
in a K-ras ⁄Erk-dependent and Wnt-dependent manner (Jung
et al.1999; Zhang et al. 2001).
The expression of gastrin, as a tumour growth factor, is
significantly increased in some colorectal cancers compared
with the low levels found in normal colonic mucosa. Onco-
genic ras has been shown to induce gastrin gene expression
through activation of the Raf-MEK-ERK signal transduction
pathway (Nakata et al. 1998; Koh et al. 2000). The Wnt sig-
nalling pathway moderately stimulates the gastrin gene pro-
moter, and Chakladar et al. (2005) found a strong (25- to
40-fold) synergistic stimulation of the gastrin promoter by
the combination of oncogenic b-catenin and K-ras overex-
pression. Deletion analysis localized the response element to
an area between )140 and )110 bp upstream of the murine
gastrin promoter. Electrophoretic mobility shift assays
detected a complex containing b-catenin ⁄Tcf, AP1, and
Smad3 ⁄4 transcription factors that bound to a DNA element
through AP1 and Smad binding sites. Gastrin promoter acti-
vation could be further enhanced or suppressed by the
co-expression of wild type Smad4 or a dominant negative
mutant of Smad4, and thus oncogenic Wnt and Ras signal-
ling pathways can synergistically induce enhanced gastrin
expression (Chakladar et al. 2005). ApcMin ⁄ + mice that over-
express one of the alternatively processed forms of gastrin,
known as glycine-extended gastrin, show a significant
increase in intestinal adenoma number. Conversely, gastrin-
deficient ApcMin ⁄ + mice showed a marked decrease in intesti-
nal adenoma number and a significantly decreased adenoma
proliferation rate (Koh et al. 2000). Thus, the real-time qRT-
PCR and immunohistochemical data from this study showing
that mutated K-ras induced enhanced expression of gastrin in
the adenomas from K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice compared
that of ApcMin mice is consistent with these published data.
Cyclo-oxygenase-2 (Cox2) has been shown to play a role
in the development of intestinal tumours, and Cox2 levels
are elevated in approximately 80–90% of human colorectal
carcinomas. Here, we showed increased Cox2 expression in
the large intestine of K-rasAsp12 ⁄Cre mice and ApcMin ⁄ + mice
relative to colon from control Cre mice, with some immuno-
histochemical evidence of increased Cox2 expression in ade-
nomas from K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mice. Mutated K-ras
is associated with increased levels of Cox2 expression in
colorectal carcinomas (Okawa et al. 2004). Cyclo-oxygenase
2 (Cox2) expression is regulated via the ras signalling path-
way, and induction of mutated ras rapidly increases Cox2
protein levels in intestinal epithelial cells. Akt (also known
as protein kinase B) is an important effector of Ras protein
signalling and a critical component of mutant ras-mediated
transformation. K-ras-mediated increase in cyclo-oxygenase-
2 mRNA stability involves activation of the protein kinase
B1 (Sheng et al. 2001). A Tcf-4-binding element (TBE) in
the Cox2 promoter has been identified that specifically binds
to Tcf-4 protein in an electrophoretic mobility shift assay.
Although b-catenin alone did not increase Cox2 protein to
detectable levels in HuH7 cells, co-expression of both
mutant b-catenin and mutant K-ras increased Cox2 protein
expression levels (Araki et al. 2003).
We showed some evidence of increased immunohisto-
chemical expression of Tiam1 (T lymphoma invasion and
metastasis 1 gene) in K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ + mouse adeno-
mas. T-cell lymphoma invasion and metastasis 1 (Tiam1)
has been shown to be an important effector pathway for
some of the effects of mutated K-ras. Tiam1) ⁄ ) mice were
shown to be resistant to the development of mutant
ras-induced skin tumours following treatment with the
carcinogen 7, 12-dimethylbenzanthracene and promoter
12-O-tetra-decanoylphorbol-13-acetate. Moreover, the few
tumours produced in Tiam1) ⁄ ) mice grew more slowly than
those in wild-type mice. T-cell lymphoma invasion and
metastasis 1 (Tiam1)-deficient primary embryonic fibroblasts
were also resistant to rasVal12-induced focus formation.
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Hence, Tiam1 was shown to be a critical regulator of ras-
induced tumour formation (Malliri et al. 2002, 2006; Baines
et al. 2005). T-cell lymphoma invasion and metastasis 1
(Tiam1) is also a Wnt-responsive gene expressed in the base
of intestinal crypts and up-regulated in Min mouse intestinal
adenomas and human colonic adenomas. Moreover, by
comparing intestinal tumour development in Apc mutant
Min mice expressing or lacking Tiam1, it was found that
Tiam1 deficiency significantly reduced the formation and
growth of intestinal tumours in vivo (Malliri et al. 2006).
In conclusion, expression of K-rasAsp12 alone in the stem
cell compartment of the adult intestinal crypt does not
significantly initiate adenoma formation, confirming our
previous findings for K-rasVal12 (Luo et al. 2007a) and those
of others (Janssen et al. 2006; Sansom et al. 2006). When
crossed on to an ApcMin ⁄ + background, the compound
mutant K-ras ⁄Cre ⁄ApcMin ⁄ + mice showed acceleration of
intestinal tumour formation, similar to that shown by others
crossing mutant K-ras and Apc mice (Janssen et al. 2006;
Sansom et al. 2006; Calcagno et al. 2008; Haigis et al.
2008). Although others have shown that the formation of
large intestinal adenomas can occur after crossing mutant K-
ras and Apc mice (Calcagno et al. 2008; Haigis et al. 2008),
this study demonstrates the impressive 5.7-fold increase in
numbers of adenomas in the large intestine compared with
the 1.5-fold increase in the small intestine, more closely
mimicking the human situation. However, whereas others
have not shown clear evidence of activation of both
Mapk ⁄Akt and Wnt ⁄Apc signalling pathways in the intesti-
nal tumours, the tumour expression studies here showed that
mutant K-ras increased activation of Mapk and Akt signal-
ling pathway targets pErk and pAkt, increased expression of
the cell cycle entry marker cyclinD2 and the stem cell mark-
ers Pem, Tcl-1 and Trap, previously shown to be activated
by mutant K-ras (Luo et al. 2007a,b), as well as increasing
the relative gene expression levels of certain Wnt pathway
targets, such as VEGF, gastrin, Cox2 and Tiam1. Other
Wnt pathway target genes such as Peroxisome proliferator-
activated receptor delta (PPARd), Matrix Metalloproteinase
7 (MMP7), PP1A and c-myc remained unchanged in
compound in mutant K-ras ⁄Cre ⁄ApcMin ⁄ + mouse adenomas
compared with ApcMin ⁄ + control mouse tumours. Cluster
analysis showed a consistent pattern of changes in gene
expression in these tumours from K-rasAsp12 ⁄Cre ⁄ApcMin ⁄ +
mice, confirming synergistic activity of mutant K-ras and
mutant Apc on their signalling pathways, as previously
suggested by others in different experimental systems, but
demonstrated here in the large intestinal adenomas forming
in vivo. Thus, these data showed that intestinal expression
of K-rasAsp12 accelerates Apc-initiated intestinal adenoma-
genesis in vivo with the greater effect on the large intestine
and provides an improved mechanistic insight showing that
this may be, at least in part, due to synergistic co-operation
between the K-ras ⁄Mapk ⁄Akt and Wnt ⁄Apc pathways
resulting in the up-regulation of certain genes.
Acknowledgements
We thank Maggie Green, Clive Lebozer and Xinping Gong
(Department of Pathology, University of Cambridge) for
technical assistance. This work was supported by grants
from CR-UK.
References
Al-Aynati M.M., Radulovich N., Riddell R.H., Tsao M.S.
(2004) Epithelial-cadherin and beta-catenin expression
changes in pancreatic intraepithelial neoplasia. Clin. Cancer
Res., 10, 1235–1240.
Andreyev H.J., Norman A.R., Cunningham D., Oates J.R.,
Clarke P.A. (1998) Kirsten ras mutations in patients with
colorectal cancer: the multicenter ‘‘RASCAL’’ study. J. Natl.
Cancer Inst., 90, 675–684.
Andreyev H.J., Norman A.R., Cunningham D. et al. (2001) Kir-
sten ras mutation in patients with colorectal cancer: the
‘‘RASCAL II’’ study. Br. J. Cancer, 85, 692–696.
Araki Y., Okamura S., Hussain S.P. et al. (2003) Regulation of
cyclooxygenase-2 expression by the Wnt and ras pathways.
Cancer Res. 63, 728–734.
Arends M.J., Frayling I. (2005). Mismatch repair deficiency in
hereditary and sporadic colorectal cancer. In: The Effective
Management of Colorectal Cancer, 4th edn, pp. 25–40 (eds
D. Cunningham, C. Topham, A. Miles), London: Aesculapius
Medical Press, Chapter 2.
Arends M.J., McGregor A.H., Toft N.J., Brown E.J., Wyllie A.H.
(1993) Susceptibility to apoptosis is differentially regulated by
c-myc and mutated Ha-ras oncogenes and is associated with
endonuclease availability. Br. J. Cancer, 68, 1127–1133.
Arends M.J., McGregor A.H., Wyllie A.H. (1994) Apoptosis is
inversely related to necrosis and determines net growth in
tumours bearing constitutively expressed myc, ras, and HPV
oncogenes. Am. J. Pathol., 144, 1045–1057.
Baines A.T., Lim K.h., Shields J.M. et al. (2005) Use of retrovi-
rus expression of interfering RNA to determine the contribu-
tion of activated K-ras and ras effector expression to human
tumour cell growth. Methods Enzymol., 407, 556–574.
Barbacid M. (1987) Ras genes. Annu. Rev. Biochem., 56,
779–827.
Bos J.L., Fearon E.R., Hamilton S.R. et al. (1987) Prevalence of
ras gene mutations in human colorectal cancers. Nature, 327,
293–297.
572 F. Luo et al.
 2009 The Authors
Journal compilation  2009 Blackwell Publishing Ltd, International Journal of Experimental Pathology, 90, 558–574
Brooks D.G., James R.M., Patek C.E., Williamson J., Arends
M.J. (2001) Mutant K-ras enhances apoptosis in embryonic
stem cells in combination with DNA damage and is associated
with increased levels of p19 ARF. Oncogene, 20, 2144–2152.
Calcagno S.R., Li S., Colon M. et al. (2008) Oncogenic K-ras
promotes early carcinogenesis in the mouse proximal colon.
Int. J. Cancer, 122, 2462–2470.
Chakladar A., Dubeykovskiy A., Wojtukiewicz L.J., Pratap J.,
Lei S., Wang T.C. (2005) Synergistic activation of the murine
gastrin promoter by oncogenic Ras and beta-catenin involves
SMAD recruitment. Biochem. Biophys. Res. Commun., 336,
190–196.
Chen L.C., Hao C.Y., Chiu Y.S. et al. (2004) Alteration of gene
expression in normal-appearing colon mucosa of APCMin
mice and human cancer patients. Cancer Res., 64, 3694–
3700.
D’Abaco G.M., Whitehead R.H., Burgess A.W. (1996) Synergy
between Apc min and an activated ras mutation is sufficient
to induce colon carcinomas. Mol. Cell. Biol., 16, 884–891.
Eisen M.B., Spellman P.T., Brown P.O., Botstein D. (1998)
Cluster analysis and display of genome-wide expression pat-
terns. Proc. Natl. Acad. Sci. U.S.A., 95, 14863–14868.
Ezzell R.M., Chafel M.M., Matsudaira P.T. (1989) Differential
localization of villin and fimbrin during development of the
mouse visceral endoderm and intestinal epithelium. Develop-
ment, 106, 407–419.
Fearon E.R., Vogelstein B. (1990) A genetic model for colorec-
tal tumourigenesis. Cell, 61, 759–767.
Fearon E.R., Hamilton S.R., Vogelstein B. (1987) Clonal analy-
sis of human colorectal tumours. Science, 238, 193–197.
Guerra C., Mijimolle N., Dhawahir A. et al. (2003) Tumor
induction by an endogenous K-ras oncogene is highly depen-
dent on cellular context. Cancer Cell, 4, 111–120.
Haigis K.M., Kendall K.R., Wang Y. et al. (2008) Differential
effects of oncogenic K-Ras and N-Ras on proliferation, differ-
entiation and tumor progression in the colon. Nat. Genet.,
40, 600–608.
Ichii S., Takeda S., Horii A. et al. (1993) Detailed analysis of
genetic alterations in colorectal tumours from patients with
and without familial adenomatous polyposis (FAP). Onco-
gene, 8, 2399–2405.
Ireland H., Kemp R., Houghton C. et al. (2004) Inducible
Cre-medated control of gene expression in the murine gastro-
intestinal tract: effect of loss of b-catenin. Gastroenterology,
126, 1236–1246.
James R.M., Arends M.J., Plowman S. et al. (2003) K-ras
proto-oncogene exhibits tumour suppressor activity as its
absence promotes tumourigenesis in murine teratomas. Mol.
Cancer Res., 1, 820–825.
Janssen K.P., Marjou F.E., Pinto D. et al. (2002) Targeted expres-
sion of oncogenic K-ras in intestinal epithelium cause spontane-
ous tumourigenesis in mice. Gastroenterology, 123, 492–504.
Janssen K.P., Abala M., EI Marjou F., Louvard D., Robine S.
(2005) Mouse models of K-ras-initiated carcinogenesis. Bio-
chim. Biophys. Acta, 1756, 145–154.
Janssen K.P., Alberici P., Fsihi H. et al. (2006) APC and onco-
genic KRAS are synergistic in enhancing Wnt signaling in
intestinal tumor formation and progression. Gastroenterol-
ogy, 131, 1096–1109.
Johnson L., Mercer K., Greenbaum D. et al. (2001) Somatic
activation of the K-ras oncogene causes early onset lung can-
cer in mice. Nature, 410, 1111–1116.
Johnson N.A., Hamoudi R.A., Ichimura K. et al. (2006)
Application of array CGH on archival formalin-fixed
paraffin-embedded tissues including small numbers of micro-
dissected cells. Lab. Invest., 86, 968–978.
Jung Y.D., Nakano K., Liu W., Gallick G., Ellis L. (1999)
Extracellular signal-regulated kinase activation is required for
up-regulation of vascular endothelial growth factor by serum
starvation in human colon carcinoma cells. Cancer Res., 59,
4804–4807.
Kim S.H., Roth K.A., Moser A.R., Gordon J.I. (1993) Trans-
genic mouse models that explore the multistep hypothesis of
intestinal neoplasia. J. Cell Biol., 123, 877–893.
Kim S.E., Lee W.J., Choi K.Y. (2007) The PI3 kinase-Akt path-
way mediates Wnt3a-induced proliferation. Cell. Signal., 19,
511–518.
Koh T., Bulitta C., Fleming J., Dockray G., Varro A., Wang T.
(2000) Gastrin is a target of the ß-catenin ⁄TCF-4 growth-sig-
naling pathway in a model of intestinal polyposis. J Clin.
Invest., 106, 533–539.
Levy D.B., Smith K.J., Beazer-Barclay Y., Hamilton S.R., Vogel-
stein B., Kinzler K.W. (1994) Inactivation of both APC alleles
in human and mouse tumours. Cancer Res., 54, 5953–5958.
Li J., Mizukami Y., Zhang X., Jo W.S., Chung D.C. (2005)
Oncogenic K-ras stimulates Wnt signaling in colon cancer
through inhibition of GSK-3 beta. Gastroenterology, 128,
1907–1918.
Luo F., Brooks D.G., Ye H. et al. (2007a) Conditional expres-
sion of mutated K-ras accelerates intestinal tumourigenesis in
Msh2-deficient mice. Oncogene, 26, 4415–4427.
Luo F., Hamoudi R., Brooks D.G., Patek C.E., Arends M.J.
(2007b) Stem cell gene expression changes induced specifically
by mutated K-ras. Gene Expr., 14, 101–115.
Maher J., Baker D.A., Manning M., Dibb N.J., Roberts I.A.G.
(1995) Evidence for cell-specific differences in transformation
by N-, H- and K-ras. Oncogene, 11, 1639–1647.
Malliri A., van der kammen R.A., Clark K., van der Valk M.,
Michiels F., Collard J. (2002) Mice deficient in the Rac acti-
vator Tiam1 are resistant to Ras-induced skin tumours. Nat-
ure, 417, 867–871.
Malliri A., Rygiel T.P., van der Kammen R.A. et al. (2006) The
rac activator Tiam1 is a Wnt-responsive gene that modifies
intestinal tumor development. J. Biol. Chem., 281, 543–548.
Mutant K-ras accelerates Min tumourigenesis 573
 2009 The Authors
Journal compilation  2009 Blackwell Publishing Ltd, International Journal of Experimental Pathology, 90, 558–574
Malumbres M., Barbacid M. (2003) RAS oncogenes: the first
30 years. Nat. Rev. Cancer, 3, 459–465.
Morris R.G., Curtis L.J., Romanowski P. et al. (1996) Ki-ras
mutations in adenomas: a characteristic of cancer-bearing
colorectal mucosa. J. Pathol., 180, 357–363.
Nakata H., Wang S.-L., Chung D.C., Westwick J.K., Tillotson
L.G. (1998) Oncogenic ras induces gastrin gene expression in
colon cancer. Gastroenterology, 115, 1144–1153.
Ohnishi T., Tomita N., Monden T. et al. (1997) A detailed
analysis of the role of K-ras gene mutation in the progression
of colorectal adenoma. Br. J. Cancer, 75, 341–347.
Okawa T., Yoshinaga K., Uetake H. et al. (2004) Cyclooxygen-
ase-2 overexpression is related to polypoid growth and K-ras
gene mutation in T1 colorectal carcinomas. Dis. Colon
Rectum, 47, 1915–1921.
Otori K., Oda Y., Sugiyama K. et al. (1997) High frequency of
K-ras mutations in human colorectal hyperplastic polyps.
Gut, 40, 660–663.
Powell S., Zilz N., Beazer-Barclay Y. et al. (1992) APC muta-
tions occur early during colorectal tumourigenesis. Nature,
359, 235–237.
Robine S., Huet C., Moll R. et al. (1985) Can villin be used to
identify malignant and undifferentiated normal digestive
epithelial cells? Proc. Natl. Acad. Sci. U.S.A., 24, 8488–
8492.
Rustgi A.K. (1994) Hereditary gastrointestinal polyposis and
nonpolyposis syndromes. N. Engl. J. Med., 331, 1694–
1702.
Sansom O.J., Meniel V., Wilkins J.A. et al. (2006) Loss of Apc
allows phenotypic manifestation of the transforming proper-
ties of an endogenous K-ras oncogene in vivo. Proc. Natl.
Acad. Sci. U.S.A., 103, 14122–14127.
Sheng H., Shao J., Dubois R.N. (2001) K-Ras-mediated increase
in cyclooxygenase 2 mRNA stability involves activation of
the protein kinase B1. Cancer Res., 61, 2670–2675.
Shivapurkar N., Huang L., Ruggeri B. et al. (1997) K-ras and
p53 mutations in aberrant crypt foci and colonic tumours
from colon cancer patients. Cancer Lett., 115, 39–46.
Sjo¨blom T., Jones S., Wood L.D. et al. (2006) The consensus
coding sequences of human breast and colorectal cancers. Sci-
ence, 314, 268–274.
Spandidos D.A., Wilkie N.M. (1984) Malignant transformation
of early passage rodent cells by a single mutated human onco-
gene. Nature, 310, 469–475.
Su L.K., Kinzler K.W., Vogelstein B. et al. (1992) Multiple
intestinal neoplasia caused by a mutation in the murine
homolog of the APC gene. Science, 256, 668–670.
Takayama T., Ohi M., Hayashi T. et al. (2001) Analysis of K-
ras, APC, and beta-catenin in aberrant crypt foci in sporadic
adenoma, cancer, and familial adenomatous polyposis. Gas-
troenterology, 121, 599–611.
Tuveson D.A., Shaw A.T., Willis N.A. et al. (2004) Endogenous
oncogenic K-ras(G12D) stimulates proliferation and wide-
spread neoplastic and developmental defects. Cancer Cell, 5,
375–387.
Wood L.D., Parsons D.W., Jones S. et al. (2007) The genomic
landscapes of human breast and colorectal cancers. Science,
318, 1108–1113.
Yun M.S., Kim S.E., Jeon S.H., Lee J.S., Choi K.Y. (2005) Both
ERK and Wnt ⁄ beta-catenin pathways are involved in Wnt3a-
induced proliferation. J. Cell Sci., 118, 313–322.
Zhang X., Gaspard J.P., Chung D.C. (2001) Regulation of
vascular endothelial growth factor by the Wnt and K-ras
pathways in colonic neoplasia. Cancer Res., 61, 6050–6054.
574 F. Luo et al.
 2009 The Authors
Journal compilation  2009 Blackwell Publishing Ltd, International Journal of Experimental Pathology, 90, 558–574
